Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring

Viktor von Wyl; Valentina Cambiano; Michael R Jordan; Silvia Bertagnolio; Alec Miners; Deenan Pillay; Jens Lundgren; Andrew N Phillips

doi:10.1371/journal.pone.0042834

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring

Viktor von Wyl, Valentina Cambiano, Michael R Jordan, Silvia Bertagnolio, Alec Miners, Deenan Pillay, Jens Lundgren, Andrew N Phillips

16 Citationer (Scopus)

Abstract

The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy.

Originalsprog	Engelsk
Tidsskrift	P L o S One
Vol/bind	7
Udgave nummer	8
Sider (fra-til)	e42834
ISSN	1932-6203
DOI	https://doi.org/10.1371/journal.pone.0042834
Status	Udgivet - 2012

Adgang til dokumentet

10.1371/journal.pone.0042834

Citationsformater

@article{fb5917cd80a94701aba89080802dbd21,

title = "Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring",

abstract = "The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy.",

author = "{von Wyl}, Viktor and Valentina Cambiano and Jordan, {Michael R} and Silvia Bertagnolio and Alec Miners and Deenan Pillay and Jens Lundgren and Phillips, {Andrew N}",

year = "2012",

doi = "10.1371/journal.pone.0042834",

language = "English",

volume = "7",

pages = "e42834",

journal = "P L o S One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "8",

}

TY - JOUR

T1 - Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring

AU - von Wyl, Viktor

AU - Cambiano, Valentina

AU - Jordan, Michael R

AU - Bertagnolio, Silvia

AU - Miners, Alec

AU - Pillay, Deenan

AU - Lundgren, Jens

AU - Phillips, Andrew N

PY - 2012

Y1 - 2012

N2 - The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy.

AB - The most recent World Health Organization (WHO) antiretroviral treatment guidelines recommend the inclusion of zidovudine (ZDV) or tenofovir (TDF) in first-line therapy. We conducted a cost-effectiveness analysis with emphasis on emerging patterns of drug resistance upon treatment failure and their impact on second-line therapy.

U2 - 10.1371/journal.pone.0042834

DO - 10.1371/journal.pone.0042834

M3 - Journal article

C2 - 22905175

SN - 1932-6203

VL - 7

SP - e42834

JO - P L o S One

JF - P L o S One

IS - 8

ER -

Cost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoring

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater